• Target：
• CdkL4

• Gene Name：
• CDKL4

• Protein Name：
• Cyclin-dependent kinase-like 4

• Human Gene Id：
• 344387

• Human Swiss Prot No：
• Q5MAI5

• Mouse Swiss Prot No：
• Q3TZA2

• Immunogen：
• The antiserum was produced against synthesized peptide derived from human CDKL4. AA range:266-315

• Specificity：
• CdkL4 Polyclonal Antibody detects endogenous levels of CdkL4 protein.

• Formulation：
• Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

• Source：
• Polyclonal, Rabbit,IgG

• Dilution：
• WB 1:500 - 1:2000. IHC 1:100 - 1:300. IF 1:200 - 1:1000. ELISA: 1:40000. Not yet tested in other applications.

• Purification：
• The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

• Concentration：
• 1 mg/ml

• Storage Stability：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• Other Name：
• CDKL4;Cyclin-dependent kinase-like 4

• Observed Band(KD)：
• 36kD

• Background：
• catalytic activity:ATP + a protein = ADP + a phosphoprotein.,domain:The [NKR]KIAxRE motif seems to be a cyclin-binding region.,similarity:Belongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. CDC2/CDKX subfamily.,similarity:Contains 1 protein kinase domain.,

• Function：
• catalytic activity:ATP + a protein = ADP + a phosphoprotein.,domain:The [NKR]KIAxRE motif seems to be a cyclin-binding region.,similarity:Belongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. CDC2/CDKX subfamily.,similarity:Contains 1 protein kinase domain.,

• Subcellular Location：
• Cytoplasm .

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs